



Type 2 NADH Dehydrogenase Is the Only Point of Entry for Electrons into the *Streptococcus agalactiae* Respiratory Chain and Is a Potential Drug Target

Andrea M. Lencina,^a Thierry Franza,^b Matthew J. Sullivan,^c  Glen C. Ulett,^c Deepak S. Ipe,^c  Philippe Gaudu,^b  Robert B. Gennis,^a  Lici A. Schurig-Briccio^a

^aDepartment of Biochemistry, University of Illinois, Urbana, Illinois, USA

^bMicalis Institute, INRA, AgroParisTech, Université Paris-Saclay, Jouy-en-Josas, France

^cSchool of Medical Sciences and Menzies Health Institute Queensland, Griffith University, Gold Coast, Australia

ABSTRACT The opportunistic pathogen *Streptococcus agalactiae* is the major cause of meningitis and sepsis in a newborn's first week, as well as a considerable cause of pneumonia, urinary tract infections, and sepsis in immunocompromised adults. This pathogen respire aerobically if heme and quinone are available in the environment, and a functional respiratory chain is required for full virulence. Remarkably, it is shown here that the entire respiratory chain of *S. agalactiae* consists of only two enzymes, a type 2 NADH dehydrogenase (NDH-2) and a cytochrome *bd* oxygen reductase. There are no respiratory dehydrogenases other than NDH-2 to feed electrons into the respiratory chain, and there is only one respiratory oxygen reductase to reduce oxygen to water. Although *S. agalactiae* grows well *in vitro* by fermentative metabolism, it is shown here that the absence of NDH-2 results in attenuated virulence, as observed by reduced colonization in heart and kidney in a mouse model of systemic infection. The lack of NDH-2 in mammalian mitochondria and its important role for virulence suggest this enzyme may be a potential drug target. For this reason, in this study, *S. agalactiae* NDH-2 was purified and biochemically characterized, and the isolated enzyme was used to screen for inhibitors from libraries of FDA-approved drugs. Zafirlukast was identified to successfully inhibit both NDH-2 activity and aerobic respiration in intact cells. This compound may be useful as a laboratory tool to inhibit respiration in *S. agalactiae* and, since it has few side effects, it might be considered a lead compound for therapeutics development.

IMPORTANCE *S. agalactiae* is part of the human intestinal microbiota and is present in the vagina of ~30% of healthy women. Although a commensal, it is also the leading cause of septicemia and meningitis in neonates and immunocompromised adults. This organism can aerobically respire, but only using external sources of heme and quinone, required to have a functional electron transport chain. Although bacteria usually have a branched respiratory chain with multiple dehydrogenases and terminal oxygen reductases, here we establish that *S. agalactiae* utilizes only one type 2 NADH dehydrogenase (NDH-2) and one cytochrome *bd* oxygen reductase to perform respiration. NADH-dependent respiration plays a critical role in the pathogen in maintaining NADH/NAD⁺ redox balance in the cell, optimizing ATP production, and tolerating oxygen. In summary, we demonstrate the essential role of NDH-2 in respiration and its contribution to *S. agalactiae* virulence and propose it as a potential drug target.

KEYWORDS bacterial pathogenesis, electron transport chain, NADH dehydrogenase, *Streptococcus agalactiae*, drug discovery

Received 9 May 2018 Accepted 7 June 2018 Published 3 July 2018

Citation Lencina AM, Franza T, Sullivan MJ, Ulett GC, Ipe DS, Gaudu P, Gennis RB, Schurig-Briccio LA. 2018. Type 2 NADH dehydrogenase is the only point of entry for electrons into the *Streptococcus agalactiae* respiratory chain and is a potential drug target. mBio 9:e01034-18. <https://doi.org/10.1128/mBio.01034-18>.

Invited Editor Neal D. Hammer, Michigan State University

Editor Kimberly A. Kline, Nanyang Technological University

Copyright © 2018 Lencina et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Lici A. Schurig-Briccio, lschurig@illinois.edu.

Streptococcus agalactiae (group B *Streptococcus* [GBS]) is a facultative, fermentative commensal bacterium normally living in the gut and urogenital tract of healthy individuals. It belongs to the family *Streptococcaceae*, many of which are opportunistic pathogens, and is able to transition to invasive niches, causing excessive inflammation, sepsis, and death (1). *S. agalactiae* is the major cause of meningitis and sepsis in a newborn's first week of life in the United States, as well as a considerable cause of pneumonia and sepsis in immunocompromised adults (2). In neonates, *S. agalactiae* is transmitted by the mother via aspiration of fluids during birth. Although most transmission can be prevented by intravenous antibiotic administration during labor, allergies and emerging resistance to such antibiotics are an increasing concern (2). *S. agalactiae* is also associated with a large fraction of urinary tract infections in the elderly and nursing home residents, including kidney and bladder infections (3).

Despite its capacity for fermentative metabolism, *S. agalactiae* can perform aerobic respiration in the presence of external sources of heme and quinone. Within the same operon, the genome encodes a cytochrome *bd* oxygen reductase (*cyt bd* encoded by *cydAB*), a putative type 2 NADH dehydrogenase (NDH-2 encoded by *ndh*), and a 1,4-dihydroxy-2-naphthoate prenyltransferase enzyme (encoded by *menA*) (4–6). The *menA* gene is normally involved in the synthesis of demethylmenaquinone (DMK-10). However, genes other than *menA* that are required to synthesize menaquinone (MK) are not present in *S. agalactiae*, which is, therefore, not able to synthesize DMK-10 from chorismate (6). Disabling *cyt bd* (Δ *cydA*) results in decreased organ colonization and increased survival of neonatal rats compared to wild-type (WT) infection, indicating a link between respiration and virulence (4, 7).

NDH-2 is a homodimeric flavoprotein that catalyzes the oxidation of NADH with the concomitant reduction of quinone. It is a monotopic membrane enzyme that binds at the cytoplasmic surface of the bacterial membrane in order to have access to one of its substrates (quinone) but has no transmembrane domain (8–11). *cyt bd* is a transmembrane, heme-containing two-subunit enzyme (CydA and CydB) that catalyzes menaquinol:O₂ oxidoreductase activity (12). The chemical reaction catalyzed by *cyt bd* results in the net electrogenic transfer of two protons from the cytoplasm to the extracellular space, contributing to the proton motive force (PMF) (12, 13). Both NDH-2 and *cyt bd* are absent in mammalian mitochondria, making them plausible drug targets (14). NDH-2, which plays an important role in pathogen survival and virulence, has been pursued as a possible drug target in *Mycobacterium tuberculosis* (15, 16), *Toxoplasma gondii* (17), and *Plasmodium falciparum* (18, 19).

To understand the significance of NDH-2 in *S. agalactiae* survival and virulence and the consequences of its deficiency, it is important to consider the main metabolic strategies used by this pathogen (Fig. 1). Glycolysis yields 2 eq each of pyruvate and NADH. Growth requires not only ATP production but also a way to recycle NADH to NAD⁺ to allow glycolysis to proceed. Figure 1 shows alternative pathways for pyruvate catabolism in *S. agalactiae* that contribute to different degrees, depending on growth conditions. Note that this organism does not have the enzymes required for the tricarboxylic acid (TCA) cycle (20).

Under anaerobic growth conditions, *S. agalactiae* must grow strictly by fermentation (21–23). Under growth conditions in which sugar metabolism is rapid and there is constant NADH production, NAD⁺ is regenerated by converting pyruvate to lactate via lactate dehydrogenase (homolactic fermentation) (Fig. 1A). Some growth conditions, however, result in a shift toward mixed-acid fermentation, in which pyruvate can be catabolized by pyruvate dehydrogenase, pyruvate formate lyase, and/or acetolactate synthase, yielding a variety of end products, including formate/CO₂, acetate, and acetoin (Fig. 1B). The presence of oxygen has several consequences. First, pyruvate formate lyase is particularly susceptible to inactivation by oxygen. Second, if both heme and quinone can be acquired from the surroundings, *S. agalactiae* utilizes its respiratory chain to regenerate NAD⁺, generate a PMF, enhance ATP production via acetate kinase (Ack) and possibly oxidative phosphorylation, and reduce the concentration of O₂ (Fig. 1C). Finally, *S. agalactiae* also has a water-forming NADH oxidase (Nox-2) (23), a




FIG 1 Pyruvate catabolism in *S. agalactiae*. One molecule of glucose will produce two of pyruvate via glycolysis, with net reduction of 2 NADH molecules. Fermentation of pyruvate, will allow NADH reoxidation for its recycling and use in a new round of glycolysis. (A) In the absence of oxygen, acetyl coenzyme A (acetyl-CoA) is made from pyruvate by pyruvate formate lyase (PFL), allowing synthesis of fatty acids. The main fermentation product is lactate, but significant amounts of ethanol, acetate, acetoin, and diacetyl are also found (21). Under aerobic conditions, production of acetoin, diacetyl, and acetate is prevalent over that of ethanol. (B) In the presence of oxygen without addition of external heme or quinone sources (respiration nonpermissive condition), lactate is still the main fermentation product, which leads to a significant decrease in pH. (C) Upon addition of external heme and quinone, in the presence of oxygen (respiration permissive condition), the respiratory chain (NDH-2/cyt *bd*) becomes functional. Metabolism is shifted toward production of acetate, acetoin, and diacetyl, reducing the amount of pyruvate available to be converted into lactate. This results in less acidification of the medium in the stationary phase. Higher growth yield is achieved as a result of enhanced ATP formation via the Pta-Ack pathway and possibly oxidative phosphorylation by the electron transport chain. Boxes indicate the main products for each condition. ACK, acetate kinase; ALS, acetolactate synthase; ALDB, 2-acetolactate decarboxylase; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase; PTA, phosphate transacetylase; n.e., nonenzymatic reaction. (Adapted with data from references 21 to 23 and 66.)

soluble enzyme that reduces oxygen to water and regenerates NAD⁺ but does not contribute to the energy needs of the cell. In the absence of heme and quinone, *S. agalactiae* relies on Nox-2 for recycling NAD⁺ to feed glycolysis, to synthesize fatty acids, and for reduction of oxygen to water.

In this study, it is demonstrated that NDH-2 is an essential element for aerobic respiration and that disabling this enzyme reduces virulence in a mouse model of systemic infection. In addition, the *S. agalactiae* NDH-2 is purified, biochemically characterized, and proven a potential drug target for GBS.

RESULTS

***S. agalactiae ndh* encodes a highly active NDH-2.** Generally, the low amino acid sequence identity among NDH-2s makes it difficult to distinguish them from other small, soluble flavoenzymes (24–26). The *S. agalactiae ndh* gene encodes a putative NDH-2 enzyme, showing relatively high identity to *Staphylococcus aureus* NdhC (42%) (27) and *Caldalkalibacillus thermarum* NDH-2 (41%) (see Fig. S1 in the supplemental material) (10, 11). The *S. agalactiae ndh* gene with an N-terminal 8×His tag was cloned and heterologously expressed in *E. coli* c43. *S. agalactiae* NDH-2 was purified, and SDS-PAGE analysis shows a single band at the predicted molecular weight of 44 kDa (Fig. 2A). The UV-visible (UV-Vis) spectrum of the air-oxidized protein shows characteristic peaks for flavin adenine dinucleotide (FAD) around 375 and 450 nm, with a shoulder around 470 nm indicating the cofactor is in an apolar environment (28) (Fig. 2B). The FAD cofactor remains in solution after precipitation of the protein with 5% trichloroacetic acid, demonstrating the flavin is noncovalently bound (29). Quantitation of the extracted flavin was calculated to be 0.25 mol FAD/mol protein. Substoichiometric flavin content is often observed with heterologously expressed flavoproteins (27, 30). Since the protein produced in *E. coli* shows substoichiometric amounts of FAD, assays were performed in the presence of 20 μM FAD. Upon addition of the flavin, a 10-fold increase in activity was observed. All results reported were performed with 20 μM FAD in the assay buffer.

Although lacking any transmembrane-spanning elements, NDH-2 is a membrane-bound protein that, upon isolation, requires the presence of detergent to remain in solution. Optimal enzyme activity and stability also required 150 to 300 mM NaCl and pH 7. NADH:quinone oxidoreductase activity was tested in the presence of NADH and different soluble quinone analogues (Fig. 2C). The *S. agalactiae* endogenous electron acceptor for NDH-2 is DMK-10 (6), a naphthoquinone, but the pure enzyme is also




FIG 2 The isolated enzyme from *S. agalactiae* is a highly active NDH-2. (A) SDS-PAGE of $\sim 5 \mu\text{g}$ of isolated protein. (B) UV-Vis spectrum of the flavin. (C) Enzyme activity was measured with different soluble quinone analogues. Data are expressed as average \pm standard deviation (SD) from three independent experiments. Q_1 , ubiquinone-1; Q_2 , ubiquinone-2; DUQ, decylubiquinone; DQ, duroquinone; MD, menadiione; DMN, 2,3-dimethyl-1,4-naphthoquinone. One hundred percent activity corresponds to $4,190 \text{ NADH s}^{-1}$ observed in the presence of Q_1 . (D) Turnover number (k_{cat}) and affinity (K_m) for the enzyme's substrates were determined. Data are expressed as average \pm SD from three independent experiments. (E) Core structures for benzoquinones (Q_1 , Q_2 , DUQ, and DQ) and naphthoquinones (MD and DMN).

active with ubiquinones (Fig. 2C and E). With 2,3-dimethyl-1,4-naphthoquinone (DMN), the soluble menaquinone analogue most similar to the natural electron acceptor in *S. agalactiae* membranes, the turnover number is about 800 NADH/s^{-1} and the K_m values for DMN and NADH are $11 \mu\text{M}$ and $28 \mu\text{M}$, respectively. The isolated *S. agalactiae* NDH-2 does not react directly with O_2 in the presence of NADH, unlike the NDH-2 from *Corynebacterium glutamicum* (31).

NDH-2 is the only entry point for electrons into the respiratory chain of *S. agalactiae*. An *ndh* deletion (Δndh) mutant was constructed to characterize the role of NDH-2 in the *S. agalactiae* respiratory metabolism. Since both aerobic respiration and Nox-2 are involved in oxygen reduction to water and regeneration of NAD^+ (23) (Fig. 1), a $\Delta ndh \Delta nox2$ double mutant strain was also constructed to characterize the effect on metabolism and oxygen tolerance. As a control, a previously studied *nox2* single-knockout strain (23) was also examined.

The WT, Δndh , $\Delta nox2$, and $\Delta ndh \Delta nox2$ strains were grown aerobically in the presence of externally added heme and quinone (referred to as the respiration permissive condition) and in the absence of heme and quinone (referred to as the respiration nonpermissive condition) (Fig. 3). When the WT or $\Delta nox2$ mutant strain is grown aerobically in the presence of external heme and quinone, enhanced ATP production results in an improved growth yield (Fig. 3A and C), and there is a metabolic shift favoring mixed-acid fermentation, reduced lactate formation, and hence, a smaller pH drop in the medium (4, 32). In contrast, the Δndh strain does not show any difference in growth rate or pH drop (Fig. 3B), likely due to an increase in consumption of glucose that results in a higher production of lactate (which has a lower pK_a) observed under nonpermissive conditions. This is to overcome the lower energetic efficiency derived from homolactic fermentation. The growth behavior and pH of the Δndh strain are restored to that of the WT strain if the deletion is complemented by a plasmid carrying the *ndh* gene under the control of its own promoter (see Fig. S2 in the supplemental material), indicating the observed effect is in fact due to NDH-2 activity. Similar results are observed for the $\Delta ndh \Delta nox2$ strain (Fig. 3D).

The effect of the deletions on oxygen utilization was tested for cells grown under either respiration permissive or nonpermissive conditions (Fig. 4A). Both respiration (NDH-2/*cyt bd*) and Nox-2 activity result in oxygen utilization. In the $\Delta ndh \Delta nox2$ double deletion strain, no oxygen utilization is observed under any circumstances, suggesting that the elimination of NDH-2 results in the complete absence of respiration.




FIG 3 The NDH-2-deficient strain shows a nonrespiratory phenotype. Growth curves and pH of the media at 8 h of culture are shown for the WT (A) and the Δndh (B), $\Delta nox2$ (C), and $\Delta ndh \Delta nox2$ (D) mutant strains. Cells were grown under respiration permissive (P [white circles and bars]) and nonpermissive (NP [black circles and bars]) conditions. Growth curves are representative of at least 3 independent experiments. pH data are plotted as the average \pm SD from three independent experiments.

When grown in the absence of heme and quinone, the WT and Δndh strains utilize oxygen at the same rate, since Nox-2 is the only enzyme contributing to the measured depletion of O₂. In the presence of heme and quinone, the WT strain has substantially more activity than the Δndh strain, since the WT strain is able to respire, while the Δndh strain cannot. All of the observed oxygen utilization of the $\Delta nox2$ strain, grown with heme and quinone, is due to NDH-2/cyt *bd* respiration. Under the conditions of these experiments and comparing the Δndh and $\Delta nox2$ strains, the capacity for O₂ utilization by the respiratory chain can be estimated to be about 6-fold higher than that for Nox-2 (Fig. 4A).




FIG 4 NDH-2 is important for respiration and for maintenance of NADH/NAD⁺ redox balance. Cells were grown under respiration permissive (white bars) or nonpermissive (black bars) conditions and harvested in early stationary phase. (A) Oxygen consumption assays were normalized to an OD₆₀₀ of 0.3 and started by the addition of 0.2% glucose. (B) The NADH/NAD⁺ ratio was determined for the WT and isogenic mutant strains. Data are plotted as the average \pm SD from three independent experiments. (A) **, $P < 0.005$ via two-way analysis of variance (ANOVA) with Tukey's posttest for the indicated comparisons. No significant difference was observed between nonpermissive and permissive conditions for the Δndh or $\Delta ndh \Delta nox2$ mutants. (B) n.s., not significant, *, $P < 0.05$, **, $P < 0.005$, and ***, $P < 0.001$, via two-way ANOVA with Dunnett's posttest compared to wild-type under nonpermissive conditions.




FIG 5 The Δndh , $\Delta nox2$, and $\Delta cydA$ mutant strains are attenuated for virulence in heart, kidney, and spleen. Mice were infected with 2×10^6 CFU of *S. agalactiae*, and bacteria were counted at 24, 48, and 72 h postinfection in heart (A), kidney (B), and spleen (C). Bacterial fitness of mutants is shown as ratio of the \log_{10} number (CFU/gram) of mutant to WT bacteria. *, $P < 0.05$, **, $P < 0.01$, and ****, $P < 0.0001$ (mutant/WT ratio), by Kruskal-Wallis test followed by Dunn's multiple comparisons. # denotes a median bacterial load (CFU per milliliter) of zero for the group.

Lastly, the importance of aerobic respiration and Nox-2 in NADH reoxidation was evaluated in cells grown under respiration permissive or nonpermissive conditions (Fig. 4B). When grown under permissive conditions, the NADH/NAD⁺ ratio did not show significant differences in the Δndh and $\Delta nox2$ strains. However, both the Δndh $\Delta nox2$ strain and the $\Delta nox2$ strain, when grown under nonpermissive conditions, show a drastic increase in NADH and the NADH/NAD⁺ ratio compared to the wild type. This suggests that NDH-2 (respiration) and Nox-2 are the major routes for NAD⁺ recycling, and these observations support the previously proposed role for respiration in fatty acid biosynthesis (23).

NDH-2 is important for *S. agalactiae* virulence. Due to the essential role of NDH-2 in *S. agalactiae* respiration, we investigated its contribution to the development of invasive disease. The bacterial burdens or fitness of the *S. agalactiae* WT and mutant strains in different organs were determined after 24, 48, and 72 h postinfection (Fig. 5). Infection assays using the *S. agalactiae* Δndh strain and Δndh $\Delta nox2$ double mutant strain revealed significant attenuation in heart and kidney colonization compared to WT (Fig. 5A and B). The $\Delta nox2$ strain is significantly attenuated in heart and spleen compared to the WT (Fig. 5A and C), as reported in previous studies (23). Unexpectedly, no pronounced phenotype is seen in any organ with the Δndh $\Delta nox2$ double mutant strain, although this double mutant does not tolerate oxygen well. In an effort to explain this, we investigated the hemolytic activity of these knockout strains (Fig. 6). The cell surface-associated β -hemolysin/cytolysin of *S. agalactiae* is a nonimmunogenic,




FIG 6 Hemolytic activity correlates with NADH/NAD⁺ ratios. Cells were grown under respiration permissive (white bars) or nonpermissive (black bars) conditions until the early stationary phase, then washed and incubated with RBCs for 1 h. Dark and light gray bars represent respiration nonpermissive and permissive growth, respectively, with 0.1% Tween 80 added to the media. Data are plotted as the average \pm standard error of the mean (SEM) from three independent experiments. *, $P < 0.0001$ via two-way ANOVA with Dunnett's posttest compared to the wild type under nonpermissive conditions.

TABLE 1 FDA-approved compounds that inhibit NDH-2 activity and *S. agalactiae* growth *in vitro*^a

Compound	IC ₅₀ (μM)	GI ₅₀ (μM)	Common use
Alexidine	16.79 ± 1.26	2.70 ± 0.51	Antiseptic
Caspofungin	15.23 ± 2.33	41.03 ± 2.62	Antifungal
Closantel	5.34 ± 0.65	0.25 ± 0.04	Anthelmintic (veterinary)
Triclabendazole	0.14 ± 0.02	15.30 ± 1.92	Anthelmintic
Zafirlukast	0.83 ± 0.07	6.07 ± 0.10	Asthma treatment

^aCells were grown under respiration permissive conditions.

oxygen-stable, pore-forming cytolysin and a red polyenic pigment (33, 34). This major virulence factor is encoded by the *cylE* gene in the *cyl* locus, a unique 12-gene operon involved in fatty acid biosynthesis (35) that is expressed by most GBS strains. This virulence factor has proapoptotic, proinflammatory, and cytotoxic effects and is necessary for full *S. agalactiae* virulence in multiple *in vivo* systems (36). Furthermore, the hemolytic pigment has been shown to protect cells against a panel of stresses (33, 37). Remarkably, increased hemolysis was observed for the double mutant compared to the Δndh strain (Fig. 6), which correlates with the dramatic increase seen for the NADH/NAD⁺ ratio (Fig. 4B). Thus, this could contribute to the rescue effect observed during infection. Consistent with this interpretation, hemolysis is restored to WT levels upon addition of 0.1% Tween 80 to the cell cultures, effectively providing fatty acids to the cells (Fig. 6).

Among the mutants tested, the strain lacking *cyt bd* ($\Delta cydA$) has been previously shown to result in changes in organ colonization in mice (7). The *cydA* knockout strain, used here as a control for *S. agalactiae* attenuation in the model of systemic infection, is significantly attenuated in heart, kidney, and spleen (Fig. 5), as well as liver (see Fig. S3 in the supplemental material), and its attenuation approaches statistical significance in blood ($P = 0.08$) (Fig. S3), findings consistent with what has been previously observed (7). None of the mutants is significantly attenuated in blood, liver, or brain colonization (Fig. S3A to C). These data support the conclusion that respiration is important for virulence in *S. agalactiae* (4, 7) and show, furthermore, that NDH-2 contributes to virulence.

Inhibitors of *S. agalactiae* NDH-2 are potential leads against GBS. Since this work demonstrates that NDH-2 is essential for respiration in *S. agalactiae* as well as important for virulence, inhibitors of the isolated enzyme were obtained and then tested as inhibitors of respiration in intact *S. agalactiae* cells. Enzymatic activity was monitored colorimetrically in the presence of NADH and menadione (MD), a commercially available soluble analogue of menaquinone. Two libraries of FDA-approved drugs were screened (about 2,000 compounds) using 25 μM each compound to test for inhibitors of the pure enzyme. Nine compounds inhibited at least 80% of enzymatic activity: alexidine, candesartan, caspofungin, closantel, hexachlorophene, isoquercetin, pramoxine, triclabendazole, and zafirlukast. Except for hexachlorophene, a relatively toxic disinfectant, all other compounds were tested against whole cells growing under respiration permissive conditions, and five of these showed an inhibitory effect on cell growth (Table 1).

Although candesartan, isoquercetin, and pramoxine are able to inhibit the purified enzyme *in vitro*, they show no effect on cell growth. On the other hand, alexidine and closantel inhibit cell growth at concentrations much lower than those required for NDH-2 inhibition, suggesting other targets might be responsible for their effect in whole cells. This is not surprising since both compounds are known to disturb membrane integrity, producing permeabilization (38) and strong uncoupling (39). Finally, caspofungin, triclabendazole, and zafirlukast not only show NDH-2 inhibition in the low micromolar and even nanomolar range but are also able to inhibit cell growth at low micromolar concentrations (Table 1).

Additional assays followed oxygen consumption of WT cells (grown with heme and quinone) in the presence of different concentrations of caspofungin, triclabendazole, or




FIG 7 Zafirlukast inhibits *S. agalactiae* respiration. Cells were grown until the early stationary phase (8 h), and the percentage of respiration was calculated after addition of different concentrations of zafirlukast (A). The percentage of respiration corresponds to the difference in oxygen consumption of cells grown under respiration permissive (P) minus nonpermissive (NP) conditions. (B and C) Overnight growth (B) and oxygen consumption (C) of the $\Delta nox2$ mutant strain in the absence or presence of 7.5 μM zafirlukast (Z). Data are plotted as the average \pm SD from three independent experiments. In panels B and C, *, $P < 0.05$, **, $P < 0.005$, and ***, $P < 0.001$, via two-way ANOVA with Tukey's posttest for the indicated comparisons. No significant difference was observed between conditions NP, NP+Z, and P+Z.

zafirlukast. From these compounds, only zafirlukast shows a dose-dependent linear decline in respiration, with 90% inhibition at 7.5 μM (Fig. 7A). In addition, the $\Delta nox2$ strain was grown overnight with and without subinhibitory concentrations of zafirlukast ($\sim 50\%$ growth inhibitory concentration [GI_{50}]), and both growth and respiration were examined after overnight incubation. The $\Delta nox2$ strain grown in the presence of zafirlukast does not exhibit enhanced growth under respiration permissive conditions compared to nonpermissive conditions. This indicates that the bacterial growth supported by the activity of the electron transport chain is substantially reduced in the presence of zafirlukast (Fig. 7B). Not all of the NDH-2 activity was eliminated since the cells were grown with a concentration of zafirlukast that does not completely inhibit the enzyme. This is shown in Fig. 7C where the oxygen utilization, which must be due to respiration in the $\Delta nox2$ strain, is substantially lower than when the cells are grown in the absence of zafirlukast, but not as low as when cells are grown in the absence of heme and quinone. In sum, the data show that zafirlukast inhibits the activity of the isolated *S. agalactiae* NDH-2 as well as the activity of the enzyme in intact cells.

DISCUSSION

S. agalactiae can cause invasive disease in newborns leading to meningitis and septicemia and is also associated with urinary tract infections in the elderly population. It is a highly adapted organism capable of metabolizing a wide variety of substrates; however, it is an obligate commensal, auxotrophic for several amino acids and vitamins (1, 20). Although it used to be considered an aerotolerant organism, *S. agalactiae* was found over 10 years ago to perform aerobic respiration in the presence of external sources of heme and quinone (4). Aerobic respiration consists of the transport of electrons through a series of redox components, from a metabolic reductant (e.g., NADH) and terminating in the reduction of oxygen to water by a terminal oxygen reductase. Importantly, respiration is linked to the generation of PMF and ATP synthesis via Ack and possibly oxidative phosphorylation (Fig. 1C).

***S. agalactiae* has a two-enzyme respiratory chain.** *S. agalactiae* has a single oxygen reductase, cyt *bd*. The first conclusion of the present work is that there is only one enzyme, NDH-2, that provides electrons to the respiratory chain of this organism. Both NDH-2 and cyt *bd* are encoded by genes (*ndh* and *cydAB*, respectively) within the same operon. Although single-subunit respiratory flavoenzymes are often misannotated (40), an exhaustive search of the genome of *S. agalactiae* shows no other genes for any additional respiratory enzymes, like glycerol-3-P dehydrogenase, pyruvate oxidase, or membrane-bound succinate, lactate, or malate dehydrogenases. A *glp* operon for glycerol metabolism is present; however, glycerol phosphate dehydrogenase (*glpD*) is replaced by a glycerol phosphate oxidase (*glpO*), as in other organisms that do not synthesize heme. The latter enzyme is soluble and reduces oxygen to hydrogen peroxide instead of reducing quinone (41). Also, whereas some bacterial pathogens (e.g., *S. aureus*) have two different NDH-2 enzymes (27), *S. agalactiae* has only one, and there is no other type of respiratory NADH dehydrogenase, such as complex I (NDH-1) or the sodium pumping NDH (Nqr) (42). Thus, unlike most other bacteria, the electron transport chain of *S. agalactiae* is not branched at either end and consists of just two proteins plus DMK-10 (6).

The *ndh* gene encodes an authentic NDH-2. The *S. agalactiae ndh* gene was cloned and expressed in *E. coli*, and the purified recombinant protein was shown to be an NADH:quinone oxidoreductase. The isolated, recombinant *S. agalactiae* NDH-2, which has an amino acid sequence identity of 42% with *S. aureus* NdhC, has a high k_{cat} (~ 800 NADH s^{-1}) that is similar to that of *S. aureus* NdhC ($\sim 1,500$ NADH s^{-1}) (27). These k_{cat} values are substantially higher than those reported for NDH-2s from other organisms, including the NDH-2s from *E. coli*, with a k_{cat} of ~ 18 NADH s^{-1} (43), *M. tuberculosis*, with a k_{cat} of ~ 10 NADH s^{-1} (44), *Bacillus pseudofirmus*, with a k_{cat} of ~ 39 NADH s^{-1} (45), *Bacillus subtilis*, with a k_{cat} of ~ 20 NADH s^{-1} (46), and *C. glutamicum*, with a k_{cat} of ~ 213 NADH s^{-1} (31). The high activities obtained for the enzymes from *S. agalactiae* and *S. aureus* are most likely due to the presence of phospholipids and FAD in the reaction buffer of our assays. The *S. agalactiae* NDH-2 has a lower K_m for NADH (11 μM) than those of other previously characterized NDH-2s from bacteria. For example, the apparent K_m value for NADH of the NDH-2 from *E. coli* is 34 μM (43), that from *B. subtilis* is 60 μM (46), that from *B. pseudofirmus* is 114 μM (45), and those from *S. aureus* are 35 μM (NdhC) and 154 μM (NdhF) (27).

Multiple advantages of utilizing aerobic respiration. *S. agalactiae* grows well by utilizing a variety of fermentation strategies (Fig. 1), but the operon encoding NDH-2 and cyt *bd* is expressed constitutively so the cells can very rapidly switch to respiratory growth (4) in the presence of O₂ after taking up quinone and heme from the environment (6, 47). Certainly, a major advantage of respiratory growth is a higher bioenergetics capacity via Ack and possibly oxidative phosphorylation. In addition to enhanced growth efficiency, respiration also serves for (i) reduction of the intracellular and local concentrations of O₂ and to combat oxygen toxicity, (ii) generation of NAD⁺ necessary for glycolysis and fatty acid synthesis (23), (iii) generation of the PMF required for powering transporters and essential efflux pumps like PefAB (13, 48), (iv) contribution

to resistance against environmental acid stress (5, 49), and (v) production of virulence factors (e.g., respiration is required for nuclease production) (50).

Respiration is linked to virulence and organ colonization. The different stimuli found in the growth environment, including the carbon source(s), concentration of O₂, and the availability of external heme and quinone, determine the metabolic pathways utilized to optimize the growth and survival of *S. agalactiae*. The growth conditions vary significantly when comparing *in vitro* batch growth to *in vivo* growth in a host animal or when comparing the *in vivo* growth in different organs. The combination of metabolic pathways utilized by *S. agalactiae* must simultaneously generate ATP, maintain the PMF, reduce levels of O₂ if it is present, and maintain the recycling of NADH through NAD⁺. Since the metabolic strategies used by *S. agalactiae* can be very different in each organ in an infected animal, it is reasonable that mutations that incapacitate respiration will have different effects on organ colonization, depending on the organ. Based on studies with a *cyt bd* oxidase deletion mutant, *S. agalactiae* respiration has been previously linked to virulence and colonization of blood-rich organs (4, 7). It is shown in the present work that the deletion of the gene encoding NDH-2 eliminates *in vitro* respiration and also results in attenuation of organ colonization in a mouse model for systemic infection. The strongest attenuation from the *ndh* deletion is in heart and kidney. The apparent significance of respiration for kidney infection may be useful considering the importance of *S. agalactiae* in urinary tract infections in the elderly (3). Moreover, *S. agalactiae* is able to synthesize its own DMK-10, starting from 1,4-DHNA (dihydroxy-2-naphthoic acid) or short-chain quinones, such as MK-4 (6), which can be found in high concentrations in the kidney (51). An unexpected finding is that the $\Delta ndh \Delta nox2$ double mutant strain is much less attenuated in kidney colonization than the highly attenuated Δndh strain (Fig. 5B). This may be related to the increased hemolysis observed for the double mutant strain compared to the Δndh strain (Fig. 6). The $\Delta ndh \Delta nox2$ double mutant strain is highly impaired in NADH oxidation to NAD⁺ (Fig. 4B), and the deficiency of NAD⁺ likely results in impaired fatty acid biosynthesis (23). The increased hemolysis observed in the double-knockout strain (Fig. 6) may be the response of *S. agalactiae* to obtain fatty acids from surrounding host cells (52).

It is noteworthy that the Δndh strain is much more impaired in colonization in the kidney than is the $\Delta cydA$ strain, since both of these mutations disrupt respiration. One possible explanation is that the presence of a heme-containing enzyme in the membrane (*cyt bd*) in the Δndh strain makes the bacterial cells more susceptible to the strong oxidative stress displayed by the kidney during sepsis (53). Alternatively, higher levels of reduced menaquinone in the $\Delta cydA$ strain could lead to production of small amounts of intracellular reactive oxygen species (ROS), stimulating a response against oxidative stress through PerR (54, 55), enhancing survival of the strain in the kidney. The precise molecular explanation for the organ-specific effects of the mutants on colonization will require further studies.

Inhibitors of *S. agalactiae* NDH-2. Screening for inhibitors against the purified *S. agalactiae* NDH-2 was done in the presence of lipids to mimic the hydrophobic environment of the enzyme *in situ*. Although several compounds from libraries of FDA-approved drugs were found to inhibit the enzyme *in vitro*, only zafirlukast also inhibits respiration in intact cells in a way that suggests NDH-2 is the likely target *in vivo*. However, it is possible that this compound has other targets in *S. agalactiae*. Zafirlukast is a cysteinyl leukotriene receptor antagonist, currently used for the prophylaxis and chronic treatment of asthma (56). It is a commercially available generic drug and safe for daily use (57), and it has also been described to have bactericidal activity against *M. tuberculosis* by inhibiting complex formation between Lsr2 (a nucleoid-associated protein) and DNA (58). Zafirlukast also has been demonstrated to have antibacterial and antibiofilm activity against the nonrespiratory oral pathogens *Porphyromonas gingivalis* and *Streptococcus mutans* (59).

TABLE 2 Bacterial strains and plasmids used in this study

Strain or plasmid	Main characteristic(s) ^a	Reference or source
Strains		
<i>S. agalactiae</i>		
NEM316	Serotype III isolated from neonatal blood culture	20
Δndh mutant	NEM316 with <i>ndh</i> gene deleted	This work
$\Delta nox2$ mutant	NEM316 <i>nox2</i> Ω <i>aphA-3</i> $\Delta nox2$ Km ^r	23
$\Delta ndh \Delta nox2$ mutant	$\Delta nox2$ mutant with <i>ndh</i> gene deleted, Km ^r	This work
NEMJ01	NEM316 <i>cydA::aphA-3</i> Km ^r	4
<i>E. coli</i>		
TG1	Host strain for sequencing	Lucigen
TOP10	Host strain for molecular cloning	Invitrogen
c43(DE3)	Host strain for protein overproduction	Avidis, France
Plasmids		
pBR322-pGHost8	Thermosensitive vector, Tet ^r	63
pTCV-lac	Shuttle vector, Ery ^r Km ^r	64
pTCV- <i>ndh</i> ^C	<i>ndh</i> complementation plasmid	This work
pET-22b	Cloning vector, Amp ^r	Novagen

^aAmp^r, Km^r, Tet^r, and Ery^r indicate resistance to ampicillin, kanamycin, tetracycline, and erythromycin, respectively.

It is worth mentioning that despite its high similarity to *S. aureus* NdhC, *S. agalactiae* NDH-2 is not inhibited by trifluoperazine or thioridazine, phenothiazines that both show a strong inhibitory effect on *S. aureus* NdhC (27). These data demonstrate that the NDH-2 enzymes from different organisms, though apparently very similar, can have different inhibition profiles with drugs. These small enzymes, with binding sites for both NADH and quinol, appear to be susceptible to inhibitors that do not bind at the substrate binding sites but, rather, to allosteric sites (44). Although the substrate binding sites may be conserved among different NDH-2s, inhibitor-binding regions may differ greatly. In any event, zafirlukast may be useful as a laboratory tool to inhibit respiration in *S. agalactiae* and, since it has few side effects (60), might be considered a lead compound for therapeutics.

MATERIALS AND METHODS

Sequence analysis. Gene sequences encoding *S. agalactiae* (gbs1788), *S. aureus* (SAB0708) and *C. thermarum* (GenBank accession no. [ZP_08531709.1](https://www.ncbi.nlm.nih.gov/nucl/511000000)) NDH-2s were retrieved from the National Center for Biotechnology Information (NCBI) database. Amino acid sequence alignments were performed using ClustalW (61).

Bacterial strains and growth conditions. Strains and plasmids used in this work are listed in Table 2. *S. agalactiae* NEM316, a capsular serotype III strain with a fully sequenced genome, was used as the WT (20, 62). For growth in liquid media, cells were initially grown overnight at 37°C in M17 broth supplemented with 0.2% glucose and 80 μ M menaquinone (MK-4), under static microaerobic conditions. These overnight cultures were used to inoculate tubes with M17 broth (1/10 vol/vol ratio) supplemented with 5 μ M riboflavin, to an initial optical density at 600 nm (OD₆₀₀) of \approx 0.05. Culture tubes were incubated at 37°C—first statically until they reached an OD₆₀₀ of \approx 0.5 and then transferred to high-aeration conditions (200 rpm). To support respiration, 50 μ g ml⁻¹ of hemoglobin (in 0.9% NaCl aqueous solution) and 30 μ M MK-4 were added to the cultures before transfer.

Construction of *ndh*-deficient mutant and complementation plasmid. Primers used for constructions are listed in Table 3. Chromosomal DNA from *S. galactiae* strain NEM316 was used as a template to amplify by PCR a DNA fragment upstream of the gene *gbs1788* (*ndh*) with primer pair gbs1788F and

TABLE 3 Primers used in this study

Primer designation	Sequence (5'→3')
gbs1788F	GATCGAATTCGATTTTCTGGCTTGACAAATGGG
gbs1788intR	GCTAGAAGTTCCTTTAAGTCCACCGGCATAACCAGCACCTAAAACCTAGG
gbs1788intF	CCTAGTTTTAGGTGCTGGTTATGCGGGTGACCTAAAGAAGCTTCTAGC
gbs1788R	GATCCGGATCCGTAACATCCATAAACCAAGG
gbs1788extF	CTGCCTCTTTTATGGATGGG
gbs1788extR	GAGCCAAAACCACTAGC
1788compFor	GCCGGAATTCGGCTATTTAAAACAAATTGGAGC
1788compRev	CGGCGGATCCCGAAGAGCTAGTTTCCTAGCTTCG
FwNdhSNdelHis	GGAATTCATATGCATCACCATCACCATCACCATCACCACACAAGAAATCCTA GTTTTAGGTGC
RvNdhSHindIII	CCCAAGCTTTTAAATGATATAAATCAAACGTCCTTAG

gbs1788intR. A second fragment downstream of *gbs1788* was obtained with primer pair gbs1788intF and gbs1788R. Both fragments were fused by PCR with gbs1788F and gbs1788R to give the fragment Δndh , which was further cloned into EcoRI and BamHI sites of the thermosensitive plasmid pBR322-pGhost8 (63) to give the plasmid pBR322-pGhost8- Δndh . The resulting plasmid was established in *E. coli* strain TG1 for sequencing and then transferred into the *S. agalactiae* NEM316 WT and $\Delta nox2$ mutant strains (23). *S. agalactiae* transformants were selected at 30°C on brain heart infusion (BHI) plates supplemented with 3 $\mu\text{g/ml}$ tetracycline. The plasmid was integrated in the *ndh* locus when cells were grown at 37°C (first recombination event), followed by growth at 30°C for excision (second recombination event). Gene deletion was confirmed by PCR with primer pair gbs1788extF and gbs1788extR, designed outside the recombination region. In the Δndh strain, 373 of 402 amino acid residues of NDH-2 protein are absent. For complementation studies, the promoter region of the operon up to downstream of the stop codon of *gbs1788* was amplified by PCR with oligonucleotide pair 1788compFor and 1788compRev and chromosomal DNA of a *gbs1789* mutant (deletion mutant) and then cloned into EcoRI/BamHI sites of plasmid pTCV-lac (64). The resulting plasmid, pTCV-*ndh*^c, was established in *E. coli* strain TG1 for sequencing and then in the Δndh mutant. pTCV-lac was used as a control. The plasmids were maintained by addition of kanamycin (Km) at 500 $\mu\text{g ml}^{-1}$.

Oxygen consumption assays and pH determination. Oxygen consumption by *S. agalactiae* cells was determined at 37°C using a dual-channel respirometer system (model S782; Strathkelvin Instruments). The concentration of oxygen in the air-saturated buffer at 37°C was assumed to be 237.5 μM . Early-stationary-phase cells (8 h) were washed and resuspended in phosphate-buffered saline (PBS) buffer to an OD of ≈ 0.3 in a 1-ml chamber; oxygen consumption was monitored after addition of 0.2% glucose. Unless specified otherwise, the effect of different compounds on respiration was determined after 3-min incubations of the cells with the drugs at 37°C before addition of glucose.

The pH of the medium at 8 h of culture was determined using pH strips (MColorphast; Millipore).

Determination of the NADH/NAD⁺ ratio. Cells grown under respiration permissive or nonpermissive conditions were collected at early stationary phase (~ 8 h) by centrifugation at $14,000 \times g$ for 5 min. Pellets were washed once with PBS and resuspended in 400 μl of extraction buffer at an OD of ~ 30 . Samples were homogenized twice in a FastPrep-24 Beadbeater at 6 m/s for 45-s cycles with 2 min of incubation on ice in between. Homogenized samples were centrifuged at 4°C in a microcentrifuge at $14,000 \times g$ for 2 min, and intracellular levels of NADH and NAD⁺ were measured using the NAD/NADH quantitation kit (MAK037; Sigma-Aldrich, St. Louis, MO) according to the manufacturer's instructions. NADH and NAD levels were normalized to milligrams of protein.

Hemolysis assay. Hemolytic activity using whole bacteria was assayed as described by Nizet et al. (65). Briefly, cells grown until the early stationary phase (~ 8 h), in the presence or absence of 0.1% Tween 80 under respiration permissive or nonpermissive conditions, were pelleted by centrifugation at $14,000 \times g$, washed once with PBS, and resuspended in 1 ml of PBS with 0.2% glucose to an OD of ~ 1 . In a 96-well conical-bottom microtiter plate, 100 μl of cell suspensions, in triplicate, was incubated with an equal volume of 1% sheep red blood cells (RBCs) in PBS-glucose. The plate was incubated at 37°C for 1 h and then spun down at $640 \times g$ for 5 min to pellet unlysed RBCs and bacteria. The supernatants were transferred to a replica 96-well plate, and hemoglobin release was measured by recording the absorbance at 420 nm. RBCs in PBS-glucose and RBC lysis with 0.1% sodium dodecyl sulfate (SDS) were used as negative and positive controls, respectively.

Animal assays. Six-week-old female BALB/c mice were purchased from the Animal Resources Centre (Australia). A systemic infection model was used to assess virulence of *S. agalactiae*. Bacteria used for inoculation were grown statically in Todd-Hewitt broth (THB) overnight at 37°C. Mice were inoculated through the lateral tail vein with 2×10^6 bacteria in PBS (pH 7.4); inocula were delivered in 200 μl using $27\text{G} \times 1\frac{1}{4}$ -in. PrecisionGlide needles (BD) connected to 1-ml tuberculin syringes. At various intervals, groups of five mice were sacrificed, and blood was collected by cardiac puncture. Organs were collected, weighed, and homogenized in PBS. The bacterial numbers in blood and organ homogenates were determined by plating on THB agar plates incubated at 37°C. Statistical analysis of bacterial counts was performed using the Kruskal-Wallis test, followed by Dunn's multiple comparisons. GraphPad Prism (version 7.0b) software was used for all statistical analyses. A *P* value of <0.05 was considered statistically significant. The animal experiments were repeated twice in independent experiments and were approved by Griffith University Animal Ethics Committee (approval no. MSC/01/15/AEC).

NDH-2 heterologous expression and purification. The *S. agalactiae* NDH-2 (*ndh* [gbs1788]) open reading frame was amplified from NEM316 using primers listed in Table 3 and cloned into the pET22-b expression plasmid, with an N-terminal 8 \times His tag. The *E. coli* c43(DE3) strain, carrying the pRARE plasmid and transformed with the resulting plasmid, was grown under aerobic conditions (200 rpm) at 37°C in LB medium supplemented with 50 $\mu\text{g/ml}$ of kanamycin and 100 $\mu\text{g/ml}$ of ampicillin until an OD₆₀₀ of ≈ 0.8 , and expression was induced with 1 mM IPTG (isopropyl- β -D-thiogalactopyranoside) for 4 h. All subsequent steps were performed at 0 to 4°C. Cells were harvested at $14,000 \times g$ for 10 min and resuspended in buffer A (50 mM sodium phosphate buffer [pH 7.5], 300 mM NaCl) plus 5 mM MgSO₄, DNase I, and protease inhibitor cocktail (Sigma). These cells were then disrupted by passing three times through a microfluidizer at a pressure of 80,000 lb/in². The resulting extracts were centrifuged at $14,000 \times g$ for 10 min to remove unbroken cells, and supernatants were subject to ultracentrifugation at $230,000 \times g$ for 4 h to obtain membrane pellets. Membrane fractions were resuspended in buffer A plus the protease inhibitor cocktail and solubilized by addition of a stock solution of 20% dodecyl- β -D-maltoside (DDM) dropwise to a final concentration of 1%. The suspension was incubated at 4°C for 1 h with mild agitation and then cleared by centrifugation at $230,000 \times g$ for 1 h. Solubilized membranes were added to 5 ml of Ni-nitrilotriacetic acid (NTA) resin (Qiagen Sciences, Germantown, MD) preequi-

brated with buffer A plus 10 mM imidazole and 0.05% DDM. The protein bound to the resin was washed with buffer A plus increasing concentrations of imidazole (10 to 50 mM) and 0.05% DDM. Protein was eluted with buffer A plus 200 mM imidazole and 0.05% DDM and concentrated by filtration (Millipore concentrator). Imidazole was removed by a series of filtration and washing steps with buffer A plus 0.05% DDM. The purified protein was stored frozen at -80°C after addition of glycerol to a final concentration of 10%.

Biochemical characterization. Protein concentration was determined using the Pierce bicinchoninic acid (BCA) protein assay kit. Purity of the sample was observed by running SDS-PAGE. The FAD concentration was measured by addition of 5% trichloroacetic acid followed by centrifugation and determination of supernatant absorbance at 450 nm (ϵ_{450} : $11,300\text{ mM}^{-1}\text{ cm}^{-1}$) (29).

Enzyme activity assay and determination of kinetic parameters. The rate of NADH oxidation was determined using a UV-Vis spectrophotometer (Agilent Technologies model 8453) by monitoring absorbance at 340 nm (NADH oxidation) upon addition of $100\text{ }\mu\text{M}$ NADH in the presence of 2 nM enzyme and a $100\text{ }\mu\text{M}$ concentration of a quinone soluble analogue. Assays were performed at 37°C in buffer B (50 mM sodium phosphate buffer [pH 7], 150 mM NaCl) plus $125\text{ }\mu\text{g ml}^{-1}$ of soy asolectin (Sigma) and $20\text{ }\mu\text{M}$ FAD. For determination of kinetic constants, 2 to $200\text{ }\mu\text{M}$ NADH and 2 to $200\text{ }\mu\text{M}$ of DMN were added to the reaction mixture containing 2 nM enzyme. Enzyme rates are expressed as a turnover number (k_{cat}) based on moles of NADH oxidized per second per mole of enzyme.

Inhibitor screening. Isolated NDH-2 activity was tested against 1,905 compounds from two FDA-approved drug libraries (Selleck Chemicals, with 1,176 compounds, and the NIH Clinical Collection [NCC], with 729 compounds). Enzyme activity was measured in buffer B with $125\text{ }\mu\text{g ml}^{-1}$ of soy asolectin, $20\text{ }\mu\text{M}$ FAD, and $50\text{ }\mu\text{M}$ MD, in the presence and absence of $25\text{ }\mu\text{M}$ each compound. The reaction was started upon addition of $100\text{ }\mu\text{M}$ NADH, after a 3-min incubation of the reaction mixture at 37°C . The compounds found to inhibit at least 80% of enzyme activity *in vitro* were further selected to determine their 50% inhibitory concentration (IC_{50}) and GI_{50} . IC_{50} refers to the concentration that causes 50% inhibition of enzyme activity, while GI_{50} represents the concentration that causes 50% inhibition of cell growth. The IC_{50} for each compound was determined by testing enzyme activity after a 3-min incubation in the presence of different concentrations of the inhibitor, before starting the reaction by addition of NADH. GI_{50} was determined by growing the bacterial cells overnight in the presence of different concentrations of each inhibitor under respiration permissive growth conditions.

SUPPLEMENTAL MATERIAL

Supplemental material for this article may be found at <https://doi.org/10.1128/mBio.01034-18>.

FIG S1, TIF file, 1.4 MB.

FIG S2, TIF file, 0.2 MB.

FIG S3, TIF file, 0.3 MB.

ACKNOWLEDGMENTS

We thank members of the Gennis laboratory for help and useful discussions.

This work was supported by grants from the United States National Institutes of Health GM095600 and HL16101 (R.B.G.) and grants from the Australia National Health and Medical Research Council APP1146569 and APP1146820 (G.C.U.).

REFERENCES

- Edwards MS, Baker CJ. 2016. Group B streptococcal infections, p 411–456. *In* Wilson CB, Nizet V, Maldonado Y, Remington JS, Klein JO (ed), Remington and Klein's infectious disease of the fetus and newborn infant, 8th ed. Elsevier, New York, NY.
- National Center for Immunization and Respiratory Diseases, Division of Bacterial Diseases. 2016. Group B Strep (GBS). Centers for Disease Control and Prevention, Atlanta, GA. <https://www.cdc.gov/groupbstrep/index.html>.
- Kline KA, Schwartz DJ, Lewis WG, Hultgren SJ, Lewis AL. 2011. Immune activation and suppression by group B streptococcus in a murine model of urinary tract infection. *Infect Immun* 79:3588–3595. <https://doi.org/10.1128/IAI.00122-11>.
- Yamamoto Y, Poyart C, Trieu-Cuot P, Lamberet G, Gruss A, Gaudu P. 2005. Respiration metabolism of group B Streptococcus is activated by environmental haem and quinone and contributes to virulence. *Mol Microbiol* 56:525–534. <https://doi.org/10.1111/j.1365-2958.2005.04555.x>.
- Rosinski-Chupin I, Sauvage E, Mairey B, Mangenot S, Ma L, Da Cunha V, Rusniok C, Bouchier C, Barbe V, Glaser P. 2013. Reductive evolution in *Streptococcus agalactiae* and the emergence of a host adapted lineage. *BMC Genomics* 14:252. <https://doi.org/10.1186/1471-2164-14-252>.
- Franza T, Delavenne E, Derré-Bobillot A, Juillard V, Boulay M, Demey E, Vinh J, Lamberet G, Gaudu P. 2016. A partial metabolic pathway enables group b streptococcus to overcome quinone deficiency in a host bacterial community. *Mol Microbiol* 102:81–91. <https://doi.org/10.1111/mmi.13447>.
- Joubert L, Dagieue JB, Fernandez A, Derré-Bobillot A, Borezée-Durant E, Fleurot I, Gruss A, Lechardeur D. 2017. Visualization of the role of host heme on the virulence of the heme auxotroph *Streptococcus agalactiae*. *Sci Rep* 7:40435. <https://doi.org/10.1038/srep40435>.
- Iwata M, Lee Y, Yamashita T, Yagi T, Iwata S, Cameron AD, Maher MJ. 2012. The structure of the yeast NADH dehydrogenase (Ndi1) reveals overlapping binding sites for water- and lipid-soluble substrates. *Proc Natl Acad Sci U S A* 109:15247–15252. <https://doi.org/10.1073/pnas.1210059109>.
- Feng Y, Li W, Li J, Wang J, Ge J, Xu D, Liu Y, Wu K, Zeng Q, Wu JW, Tian C, Zhou B, Yang M. 2012. Structural insight into the type-II mitochondrial NADH dehydrogenases. *Nature* 491:478–482. <https://doi.org/10.1038/nature11541>.
- Heikal A, Nakatani Y, Dunn E, Weimar MR, Day CL, Baker EN, Lott JS, Sazanov LA, Cook GM. 2014. Structure of the bacterial type II NADH dehydrogenase: a monotopic membrane protein with an essential role in energy generation. *Mol Microbiol* 91:950–964. <https://doi.org/10.1111/mmi.12507>.
- Nakatani Y, Jiao W, Aragão D, Shimaki Y, Petri J, Parker EJ, Cook GM.

2017. Crystal structure of type II NADH:quinone oxidoreductase from *Caldalkalibacillus thermanus* with an improved resolution of 2.15 Å. *Acta Crystallogr Sect F Struct Biol Commun* 73:541–549. <https://doi.org/10.1107/S2053230X17013073>.
12. Borisov VB, Gennis RB, Hemp J, Verkhorvsky MI. 2011. The cytochrome bd respiratory oxygen reductases. *Biochim Biophys Acta* 1807:1398–1413. <https://doi.org/10.1016/j.bbabi.2011.06.016>.
 13. Brooijmans RJ, Poolman B, Schuurman-Wolters GK, de Vos WM, Hugenholtz J. 2007. Generation of a membrane potential by *Lactococcus lactis* through aerobic electron transport. *J Bacteriol* 189:5203–5209. <https://doi.org/10.1128/JB.00361-07>.
 14. Cook GM, Greening C, Hards K, Berney M. 2014. Energetics of pathogenic bacteria and opportunities for drug development. *Adv Microb Physiol* 65:1–62. <https://doi.org/10.1016/bs.ampbs.2014.08.001>.
 15. Weinstein EA, Yano T, Li LS, Avarbock D, Avarbock A, Helm D, McColm AA, Duncan K, Lonsdale JT, Rubin H. 2005. Inhibitors of type II NADH:menaquinone oxidoreductase represent a class of antitubercular drugs. *Proc Natl Acad Sci U S A* 102:4548–4553. <https://doi.org/10.1073/pnas.0500469102>.
 16. Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, Gennaro ML. 2005. Changes in energy metabolism of *Mycobacterium tuberculosis* in mouse lung and under *in vitro* conditions affecting aerobic respiration. *Proc Natl Acad Sci U S A* 102:15629–15634. <https://doi.org/10.1073/pnas.0507850102>.
 17. Lin SS, Gross U, Bohne W. 2009. Type II NADH dehydrogenase inhibitor 1-hydroxy-2-dodecyl-4(1H)quinolone leads to collapse of mitochondrial inner-membrane potential and ATP depletion in *Toxoplasma gondii*. *Eukaryot Cell* 8:877–887. <https://doi.org/10.1128/EC.00381-08>.
 18. Biagini GA, Fisher N, Shone AE, Mubarak MA, Srivastava A, Hill A, Antoine T, Warman AJ, Davies J, Pidathala C, Amewu RK, Leung SC, Sharma R, Gibbons P, Hong DW, Pacorel B, Lawrenson AS, Charoensuthivarakul S, Taylor L, Berger O, Mbekeani A, Stocks PA, Nixon GL, Chadwick J, Hemingway J, Delves MJ, Sinden RE, Zeeman AM, Kocken CH, Berry NG, O'Neill PM, Ward SA. 2012. Generation of quinolone antimalarials targeting the *Plasmodium falciparum* mitochondrial respiratory chain for the treatment and prophylaxis of malaria. *Proc Natl Acad Sci U S A* 109:8298–8303. <https://doi.org/10.1073/pnas.1205651109>.
 19. Yang Y, Yu Y, Li X, Li J, Wu Y, Yu J, Ge J, Huang Z, Jiang L, Rao Y, Yang M. 2017. Target elucidation by cocrystal structures of NADH-ubiquinone oxidoreductase of *Plasmodium falciparum* (PfNDH2) with small molecule to eliminate drug-resistant malaria. *J Med Chem* 60:1994–2005. <https://doi.org/10.1021/acs.jmedchem.6b01733>.
 20. Glaser P, Rusniok C, Buchrieser C, Chevalier F, Frangeul L, Msadek T, Zouine M, Couvé E, Lalioui L, Poyart C, Trieu-Cuot P, Kunst F. 2002. Genome sequence of *Streptococcus agalactiae*, a pathogen causing invasive neonatal disease. *Mol Microbiol* 45:1499–1513. <https://doi.org/10.1046/j.1365-2958.2002.03126.x>.
 21. Garrigues C, Loubiere P, Lindley ND, Coccain-Bousquet M. 1997. Control of the shift from homolactic acid to mixed-acid fermentation in *Lactococcus lactis*: predominant role of the NADH/NAD⁺ ratio. *J Bacteriol* 179:5282–5287. <https://doi.org/10.1128/jb.179.17.5282-5287.1997>.
 22. Higuchi M, Yamamoto Y, Poole LB, Shimada M, Sato Y, Takahashi N, Kamio Y. 1999. Functions of two types of NADH oxidases in energy metabolism and oxidative stress of *Streptococcus mutans*. *J Bacteriol* 181:5940–5947.
 23. Yamamoto Y, Pargade V, Lamberet G, Gaudu P, Thomas F, Texereau J, Gruss A, Trieu-Cuot P, Poyart C. 2006. The group B *Streptococcus* NADH oxidase Nox-2 is involved in fatty acid biosynthesis during aerobic growth and contributes to virulence. *Mol Microbiol* 62:772–785. <https://doi.org/10.1111/j.1365-2958.2006.05406.x>.
 24. Bandejas TM, Salgueiro C, Kletzin A, Gomes CM, Teixeira M. 2002. *Acidianus ambivalens* type-II NADH dehydrogenase: genetic characterization and identification of the flavin moiety as FMN. *FEBS Lett* 531:273–277. [https://doi.org/10.1016/S0014-5793\(02\)03514-7](https://doi.org/10.1016/S0014-5793(02)03514-7).
 25. Brito JA, Bandejas TM, Teixeira M, Vonnrhein C, Archer M. 2006. Crystallisation and preliminary structure determination of a NADH:quinone oxidoreductase from the extremophile *Acidianus ambivalens*. *Biochim Biophys Acta* 1764:842–845. <https://doi.org/10.1016/j.bbapap.2005.09.015>.
 26. Brito JA, Sousa FL, Stelter M, Bandejas TM, Vonnrhein C, Teixeira M, Pereira MM, Archer M. 2009. Structural and functional insights into sulfide:quinone oxidoreductase. *Biochemistry* 48:5613–5622. <https://doi.org/10.1021/bi9003827>.
 27. Schurig-Briccio LA, Yano T, Rubin H, Gennis RB. 2014. Characterization of the type 2 NADH:menaquinone oxidoreductases from *Staphylococcus aureus* and the bactericidal action of phenothiazines. *Biochim Biophys Acta* 1837:954–963. <https://doi.org/10.1016/j.bbabi.2014.03.017>.
 28. Ghisla S, Massey V. 1986. New flavins for old: artificial flavins as active site probes of flavoproteins. *Biochem J* 239:1–12. <https://doi.org/10.1042/bj2390001>.
 29. Moore EG, Cardemil E, Massey V. 1978. Production of a covalent flavin linkage in lipoamide dehydrogenase. Reaction with 8-Cl⁻FAD. *J Biol Chem* 253:6413–6422.
 30. Venkatakrishnan P, Lencina AM, Schurig-Briccio LA, Gennis RB. 2013. Alternate pathways for NADH oxidation in *Thermus thermophilus* using type 2 NADH dehydrogenases. *Biol Chem* 394:667–676. <https://doi.org/10.1515/hsz-2012-0333>.
 31. Nantapong N, Otofujii A, Migita CT, Adachi O, Toyama H, Matsushita K. 2005. Electron transfer ability from NADH to menaquinone and from NADPH to oxygen of type II NADH dehydrogenase of *Corynebacterium glutamicum*. *Biosci Biotechnol Biochem* 69:149–159. <https://doi.org/10.1271/bbb.69.149>.
 32. Pedersen MB, Gaudu P, Lechardeur D, Petit MA, Gruss A. 2012. Aerobic respiration metabolism in lactic acid bacteria and uses in biotechnology. *Annu Rev Food Sci Technol* 3:37–58. <https://doi.org/10.1146/annurev-food-022811-101255>.
 33. Whidbey C, Harrell MI, Burnside K, Ngo L, Becraft AK, Iyer LM, Aravind L, Hitti J, Adams Waldorf KM, Rajagopal L. 2013. A hemolytic pigment of group B *Streptococcus* allows bacterial penetration of human placenta. *J Exp Med* 210:1265–1281. <https://doi.org/10.1084/jem.20122753>.
 34. Rosa-Fraile M, Dramsi S, Spellerberg B. 2014. Group B streptococcal haemolysin and pigment, a tale of twins. *FEMS Microbiol Rev* 38:932–946. <https://doi.org/10.1111/1574-6976.12071>.
 35. Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V. 2001. Genetic basis for the beta-hemolytic/cytolytic activity of group B *Streptococcus*. *Mol Microbiol* 39:236–247. <https://doi.org/10.1046/j.1365-2958.2001.02211.x>.
 36. Barnett TC, Cole JN, Rivera-Hernandez T, Henningham A, Paton JC, Nizet V, Walker MJ. 2015. Streptococcal toxins: role in pathogenesis and disease. *Cell Microbiol* 17:1721–1741. <https://doi.org/10.1111/cmi.12531>.
 37. Liu GY, Doran KS, Lawrence T, Turkson N, Puliti M, Tissi L, Nizet V. 2004. Sword and shield: linked group B streptococcal beta-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. *Proc Natl Acad Sci U S A* 101:14491–14496. <https://doi.org/10.1073/pnas.0406143101>.
 38. McDonnell G, Russell AD. 1999. Antiseptics and disinfectants: activity, action, and resistance. *Clin Microbiol Rev* 12:147–179.
 39. Bacon JA, Ulrich RG, Davis JP, Thomas EM, Johnson SS, Conder GA, Sangster NC, Rothwell JT, McCracken RO, Lee BH, Clothier MF, Geary TG, Thompson DP. 1998. Comparative *in vitro* effects of closantel and selected beta-ketoamide anthelmintics on a gastrointestinal nematode and vertebrate liver cells. *J Vet Pharmacol Ther* 21:190–198. <https://doi.org/10.1046/j.1365-2885.1998.00139.x>.
 40. Fuller JR, Vitko NP, Perkowski EF, Scott E, Khatri D, Spontak JS, Thurlow LR, Richardson AR. 2011. Identification of a lactate-quinone oxidoreductase in *Staphylococcus aureus* that is essential for virulence. *Front Cell Infect Microbiol* 1:19. <https://doi.org/10.3389/fcimb.2011.00019>.
 41. Colussi T, Parsonage D, Boles W, Matsuoka T, Mallett TC, Karplus PA, Claiborne A. 2008. Structure of alpha-glycerophosphate oxidase from *Streptococcus* sp.: a template for the mitochondrial alpha-glycerophosphate dehydrogenase. *Biochemistry* 47:965–977. <https://doi.org/10.1021/bi701685u>.
 42. Kerscher S, Dröse S, Zickermann V, Brandt U. 2008. The three families of respiratory NADH dehydrogenases. *Results Probl Cell Differ* 45:185–222. https://doi.org/10.1007/400_2007_028.
 43. Björklöf K, Zickermann V, Finel M. 2000. Purification of the 45 kDa, membrane bound NADH dehydrogenase of *Escherichia coli* (NDH-2) and analysis of its interaction with ubiquinone analogues. *FEBS Lett* 467:105–110. [https://doi.org/10.1016/S0014-5793\(00\)01130-3](https://doi.org/10.1016/S0014-5793(00)01130-3).
 44. Yano T, Li LS, Weinstein E, Teh JS, Rubin H. 2006. Steady-state kinetics and inhibitory action of antitubercular phenothiazines on *Mycobacterium tuberculosis* type-II NADH-menaquinone oxidoreductase (NDH-2). *J Biol Chem* 281:11456–11463. <https://doi.org/10.1074/jbc.M508844200>.
 45. Liu J, Krulwich TA, Hicks DB. 2008. Purification of two putative type II NADH dehydrogenases with different substrate specificities from alkaliphilic *Bacillus pseudofirmus* OF4. *Biochim Biophys Acta* 1777:453–461. <https://doi.org/10.1016/j.bbabi.2008.02.004>.
 46. Bergsma J, Van Dongen MB, Konings WN. 1982. Purification and character-

- ization of NADH dehydrogenase from *Bacillus subtilis*. Eur J Biochem 128: 151–157. <https://doi.org/10.1111/j.1432-1033.1982.tb06945.x>.
47. Rezaïki L, Lamberet G, Derré A, Gruss A, Gaudu P. 2008. *Lactococcus lactis* produces short-chain quinones that cross-feed group B *Streptococcus* to activate respiration growth. Mol Microbiol 67:947–957. <https://doi.org/10.1111/j.1365-2958.2007.06083.x>.
 48. Fernandez A, Lechardeur D, Derré-Bobillot A, Couvé E, Gaudu P, Gruss A. 2010. Two coregulated efflux transporters modulate intracellular heme and protoporphyrin IX availability in *Streptococcus agalactiae*. PLoS Pathog 6:e1000860. <https://doi.org/10.1371/journal.ppat.1000860>.
 49. Shabayek S, Spellerberg B. 2017. Acid stress response mechanisms of group B streptococci. Front Cell Infect Microbiol 7:395. <https://doi.org/10.3389/fcimb.2017.00395>.
 50. Derré-Bobillot A, Cortes-Perez NG, Yamamoto Y, Kharrat P, Couvé E, Da Cunha V, Decker P, Boissier MC, Escartin F, Cesselin B, Langella P, Bermúdez-Humarán LG, Gaudu P. 2013. Nuclease A (Gbs0661), an extracellular nuclease of *Streptococcus agalactiae*, attacks the neutrophil extracellular traps and is needed for full virulence. Mol Microbiol 89: 518–531. <https://doi.org/10.1111/mmi.12295>.
 51. Shearer MJ, Newman P. 2014. Recent trends in the metabolism and cell biology of vitamin K with special reference to vitamin K cycling and MK-4 biosynthesis. J Lipid Res 55:345–362. <https://doi.org/10.1194/jlr.R045559>.
 52. Brinster S, Lamberet G, Staels B, Trieu-Cuot P, Gruss A, Poyart C. 2009. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature 458:83–86. <https://doi.org/10.1038/nature07772>.
 53. Ratliff BB, Abdulmahdi W, Pawar R, Wolin MS. 2016. Oxidant mechanisms in renal injury and disease. Antioxid Redox Signal 25:119–146. <https://doi.org/10.1089/ars.2016.6665>.
 54. Horsburgh MJ, Clements MO, Crossley H, Ingham E, Foster SJ. 2001. PerR controls oxidative stress resistance and iron storage proteins and is required for virulence in *Staphylococcus aureus*. Infect Immun 69: 3744–3754. <https://doi.org/10.1128/IAI.69.6.3744-3754.2001>.
 55. Henningham A, Döhrmann S, Nizet V, Cole JN. 2015. Mechanisms of group A *Streptococcus* resistance to reactive oxygen species. FEMS Microbiol Rev 39:488–508. <https://doi.org/10.1093/femsre/fuu009>.
 56. American Society of Health-System Pharmacists, Inc. 2009. Zafirlukast. American Society of Health-System Pharmacists, Inc., Bethesda, MD. <https://medlineplus.gov/druginfo/meds/a697007.html>. Accessed 24 October 2017
 57. Dekhuijzen PN, Koopmans PP. 2002. Pharmacokinetic profile of zafirlukast. Clin Pharmacokinet 41:105–114. <https://doi.org/10.2165/00003088-200241020-00003>.
 58. Pinault L, Han JS, Kang CM, Franco J, Ronning DR. 2013. Zafirlukast inhibits complexation of Lsr2 with DNA and growth of *Mycobacterium tuberculosis*. Antimicrob Agents Chemother 57:2134–2140. <https://doi.org/10.1128/AAC.02407-12>.
 59. Gerits E, Van der Massen I, Vandamme K, De Cremer K, De Brucker K, Thevissen K, Cammue BPA, Beullens S, Fauvart M, Verstraeten N, Michiels J, Roberts M. 2017. *In vitro* activity of the antiasthmatic drug zafirlukast against the oral pathogens *Porphyromonas gingivalis* and *Streptococcus mutans*. FEMS Microbiol Lett 364. <https://doi.org/10.1093/femsle/fnx005>.
 60. Calhoun WJ. 1998. Summary of clinical trials with zafirlukast. Am J Respir Crit Care Med 157:S238–S246. <https://doi.org/10.1164/ajrccm.157.6.mar6>.
 61. Thompson JD, Higgins DG, Gibson TJ. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res 22:4673–4680. <https://doi.org/10.1093/nar/22.22.4673>.
 62. Gaillot O, Poyart C, Berche P, Trieu-Cuot P. 1997. Molecular characterization and expression analysis of the superoxide dismutase gene from *Streptococcus agalactiae*. Gene 204:213–218. [https://doi.org/10.1016/S0378-1119\(97\)00548-9](https://doi.org/10.1016/S0378-1119(97)00548-9).
 63. Biswas I, Gruss A, Ehrlich SD, Maguin E. 1993. High-efficiency gene inactivation and replacement system for Gram-positive bacteria. J Bacteriol 175:3628–3635. <https://doi.org/10.1128/jb.175.11.3628-3635.1993>.
 64. Poyart C, Trieu-Cuot P. 1997. A broad-host-range mobilizable shuttle vector for the construction of transcriptional fusions to beta-galactosidase in Gram-positive bacteria. FEMS Microbiol Lett 156:193–198. <https://doi.org/10.1111/j.1574-6968.1997.tb12726.x>.
 65. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE. 1996. Group B streptococcal beta-hemolysin expression is associated with injury of lung epithelial cells. Infect Immun 64:3818–3826.
 66. Cretenet M, Le Gall G, Wegmann U, Even S, Shearman C, Stentz R, Jeanson S. 2014. Early adaptation to oxygen is key to the industrially important traits of *Lactococcus lactis* ssp. *cremoris* during milk fermentation. BMC Genomics 15:1054. <https://doi.org/10.1186/1471-2164-15-1054>.
 67. Robert X, Gouet P. 2014. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res 42:W320–W324. <https://doi.org/10.1093/nar/gku316>.